The MedWatch June 2015 safety labeling changes were published yesterday, and updated the warnings for Xeljanz (tofacitinib). "The risk of herpes zoster is increased in patients treated with Xeljanz and appears to be higher in patients treated with Xeljanz in Japan."
All News
NEJM reports a 52 week, phase II trial in 293 adult patients with moderate-to-severe psoriasis (>10 BSA) who were randomized to receive either placebo, adalimumab or guselkumab - a novel IL-23 inhibitor.
On May 26, RheumNow.com reported that Amgen and Astra-Zenica suspended drug development for the IL-17 inhibitor brodalumab.
Demyelinating disorders are an uncommon complication of TNF inhibition and have been described with all TNF inhibitors but also with other biologics.
Based on recently released data, ProPublica.org has compiled a list of pharmaceutical payments made to 606,000 US physicians in the last year. Their analysis turned up big differences between the different specialties.
In a prospective study of 311 rheumatoid arthritis patients starting either adalimumab (ADA) or etanercept, investigators sought to correlate drug levels and/or anti-drug antibodies with clinical outcomes (citation source http://url.ie/z237).
Regenerative medicine and the use of bone marrow stromal cells (or mesenchymal stem cells - MSC) is controversial in many areas of medicine, including osteoarthritis. MSC use is at a very early stage in orthopedic research, but has been investigated in osteoarthritis of the kn
In a 2 year follow-up of the DESIR cohort of patients with early inflammatory back pain (627 patients), TNF inhibitor use was associated with a significantly greater decrease in the median NSAID intake (from 54.9 to 1.9 in TNFi pts versus from 41.9 to 22.3 in non-TNFi pts, p0.05).
615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks.
Using drug survival as a global measure of a drug's effectiveness, safety and tolerability, UK investigators used a national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register) to compare survival rates of the first biologic used in 3,523 biologic-naiv
A prospective cohort of 331 patients tested for anti-adalimumab (n=160) and anti-etanercept (n-171) antibodies after initiation of their TNF inhibitor therapy.
Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.
Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments.
A large ACP survey of over 18,000 US internal medicine residents shows they often incorporate cost of care in discussions and decisions, but may not know the data (citation source http://buff.ly/1KeLq0D).
Rheumatoid management hinges on choosing your best therapies first.
Biosimilars are copies of the biologic medicines used to treat inflammatory and immunologic conditions such as rheumatoid arthritis, multiple sclerosis and cancer- potentially at lower costs.
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
The National Institute for Heath and Care Excellence has turned down Otezla for coverage under the U.K. healthcare system for psoriatic arthritis.
Idiopathic pulmonary fibrosis carries a high mortality rate and can be a management challenge. Moreover, exacerbations of IPF may be fatal. A multicenter uncontrolled study examined the utility of targeting autoantibody production with revealed surprising results.
